Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma’s Strategic Investment to Support the Development of Taysha’s AAV-based Gene Therapy Programs
October 24, 2022 19:35 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs
October 24, 2022 19:30 ET
|
Taysha Gene Therapies, Inc.
- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha’s novel product candidates for rare monogenic...
Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)
October 06, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
TSHA-120 treated patients in GAN demonstrated durable improvement and recoverability of sensory nerve amplitude potential (SNAP), a definitive clinical endpoint, compared to natural history TSHA-120...
Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11
August 09, 2022 17:22 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Gene Therapies to Participate in Upcoming August Investor Conferences
August 01, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
BTIG Biotechnology Conference on August 8, 2022 at 12:00 pm ET 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022 at 9:45 am ET DALLAS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Taysha...
Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022
July 06, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
DALLAS, July 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Gene Therapies Announces Annual Stockholder Meeting
June 13, 2022 08:39 ET
|
Taysha Gene Therapies, Inc.
DALLAS, June 13, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Gene Therapies to Participate in Upcoming June Investor Conferences and Convention
June 02, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
Jefferies Healthcare Conference on June 8, 2022 at 9:30 am ET Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at 11:20 am PT BIO International Convention on June 15, 2022 at...
Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
Initiated clinical development of TSHA-102 for Rett Syndrome under recently approved Clinical Trial Application (CTA) with preliminary Phase 1/2 data expected by year-end 2022 Received Orphan Drug...